1,115 reports of this reaction
4.9% of all CRIZOTINIB reports
#3 most reported adverse reaction
NEOPLASM PROGRESSION is the #3 most commonly reported adverse reaction for CRIZOTINIB, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 1,115 FDA adverse event reports linking CRIZOTINIB to NEOPLASM PROGRESSION. This represents approximately 4.9% of all 22,895 adverse event reports for this drug.
Patients taking CRIZOTINIB who experience neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEOPLASM PROGRESSION is moderately reported among CRIZOTINIB users, representing a notable but not dominant share of adverse events.
In addition to neoplasm progression, the following adverse reactions have been reported for CRIZOTINIB:
The following drugs have also been linked to neoplasm progression in FDA adverse event reports:
NEOPLASM PROGRESSION has been reported as an adverse event in 1,115 FDA reports for CRIZOTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEOPLASM PROGRESSION accounts for approximately 4.9% of all adverse event reports for CRIZOTINIB, making it one of the most commonly reported side effect.
If you experience neoplasm progression while taking CRIZOTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.